Cover Image
市場調查報告書

全球單株抗體開發平台分析

Global Monoclonal Antibodies Pipeline Analysis

出版商 PNS Pharma 商品編碼 302560
出版日期 內容資訊 英文 1360 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球單株抗體開發平台分析 Global Monoclonal Antibodies Pipeline Analysis
出版日期: 2014年01月01日 內容資訊: 英文 1360 Pages
簡介

單株抗體(mAB)已成了醫藥品產業最急速成長的部門。2012年FDA核可的單株抗體治療藥就有30種以上,年度銷售額達到400億美金以上。

本報告提供全球單株抗體型治療藥相關的總括性調查,提供概要及各種開發階段的分析,替代藥物的名字,起作用的適應症,開發階段,作用機制,品牌名,專利資訊,彙整不同適應症·國家·不同組織的orphan指定,及臨床實驗國等分析,為您概述為以下內容。

第1章 全球單株抗體市場概要

第2章 單株抗體臨床開發階段:未確認

  • 概要
  • 臨床階段的單株抗體藥簡介

第3章 單株抗體臨床開發階段:研究

第4章 單株抗體臨床開發階段:前臨床

第5章 單株抗體臨床開發階段:臨床

第6章 單株抗體臨床開發階段:PhaseⅠ

第7章 單株抗體臨床開發階段:PhaseⅠ/Ⅱ

第8章 單株抗體臨床開發階段:PhaseⅡ

第9章 單株抗體臨床開發階段:PhaseⅡ/Ⅲ

第10章 單株抗體臨床開發階段:PhaseⅢ

第11章 單株抗體階段:事前登記

第12章 單株抗體:登記完畢

第13章 上市

圖表清單

目錄

The market for monoclonal antibodies (mAB) has become the fastest growing segment of the pharmaceutical industry. In 2012, there were more than 30 monoclonal antibody therapies approved by the FDA which generated annual sales of more than US$ 40 Billion. As the therapeutic mABs already play a significant part in effective medical treatment, it is most likely that their importance would increase by manyfolds in the future.

There has been a continuous rise in the market for therapeutic monoclonal in recent years. In 2012, there were more than 25 monoclonals in US and the EU. Currently, there are about 10 monoclonals which have already achieved category of "blockbuster", that is they are widely used medications that have been able to generate profits of more than US$ 1 Billion (each) to companies that market them. It has been estimated that in 2012, the global sales of antibody-based therapeutic products was around US$ 55 Billion.

"Global Monoclonal Antibodies Pipeline Analysis" by PNS Pharma gives comprehensive insight on the various Monoclonal Antibodies based drugs being developed for the treatment of multiple diseases. Research report covers all Monoclonal Antibodies based being developed in various development phases. This report enables pharmaceutical companies, collaborators and other associated stake holders to identify and analyze the available investment opportunity in the Monoclonal Antibodies market based upon development process.

Following parameters for each orphan designated drug profile in development phase are covered in "Global Monoclonal Antibodies Pipeline Analysis" research report:

  • Drug Profile Overview
  • Alternate Names for Drug
  • Active Indication
  • Phase of Development
  • Mechanism of Action
  • Brand Name
  • Patent Information
  • Orphan Designation by Indication, Country & Organisation
  • Country for Clinical Trial
  • Owner / Originator/ Licensee/Collaborator
  • Administrative Route
  • Drug Class
  • ATC Codes

Global Monoclonal Antibodies Pipeline by Clinical Phase:

  • Research: 117
  • Preclinical: 426
  • Clinical: 11
  • Phase-0: 1
  • Phase-I: 183
  • Phase-I/II: 35
  • Phase-II: 159
  • Phase-II/III: 7
  • Phase-III: 64
  • Preregistration: 4
  • Registered: 2
  • Marketed: 56
  • Unknown: 7

Table of Contents

1. Global Monoclonal Antibodies Market Overview

2. Monoclonal Antibodies Clinical Development Phase: Unknown

  • 2.1. Overview
  • 2.2. Monoclonal Antibodies Drug Profile in Clinical Phase

3. Monoclonal Antibodies Clinical Development Phase: Research

  • 3.1. Overview
  • 3.2. Monoclonal Antibodies Drug Profile in Clinical Phase

4. Monoclonal Antibodies Clinical Development Phase: Preclinical

  • 4.1. Overview
  • 4.2. Monoclonal Antibodies Drug Profile in Clinical Phase

5. Monoclonal Antibodies Clinical Development Phase: Clinical

  • 5.1. Overview
  • 5.2. Monoclonal Antibodies Drug Profile in Clinical Phase

6. Monoclonal Antibodies Clinical Development Phase: Phase-0

  • 6.1. Overview
  • 6.2. Monoclonal Antibodies Drug Profile in Clinical Phase

7. Monoclonal Antibodies Clinical Development Phase: Phase-I

  • 7.1. Overview
  • 7.2. Monoclonal Antibodies Drug Profile in Clinical Phase

8. Monoclonal Antibodies Clinical Development Phase: Phase-I/II

  • 8.1. Overview
  • 8.2. Monoclonal Antibodies Drug Profile in Clinical Phase

9. Monoclonal Antibodies Clinical Development Phase: Phase-II

  • 9.1. Overview
  • 9.2. Monoclonal Antibodies Drug Profile in Clinical Phase

10. Monoclonal Antibodies Clinical Development Phase: Phase-II/III

  • 10.1. Overview
  • 10.2. Monoclonal Antibodies Drug Profile in Clinical Phase

11. Monoclonal Antibodies Clinical Development Phase: Phase-III

  • 11.1. Overview
  • 11.2. Monoclonal Antibodies Drug Profile in Clinical Phase

12. Monoclonal Antibodies Clinical Development Phase: Preregistration

  • 12.1. Overview
  • 12.2. Monoclonal Antibodies Drug Profile in Clinical Phase

13. Monoclonal Antibodies Clinical Development Phase: Registered

  • 13.1. Overview
  • 13.2. Monoclonal Antibodies Drug Profile in Clinical Phase

14. Marketed

  • 14.1. Overview
  • 14.2. Marketed Monoclonal Antibodies Drug Profile

List of Table

Each Drug Profile has Tables Representing Following Information:

  • Alternate Names
  • Originator & Owner
  • Collaborator
  • Technology Provider
  • Licensee
  • Highest Development Phase
  • Indications
  • Class
  • Mechanism of Action
  • ATC Code
  • Designated Brand Name
Back to Top